Lorillard Bonds Attractive Ahead of FDA Ruling
Worries about the FDA's ruling on the relative safety of menthol cigarettes have left Lorillard's bonds looking attractively priced according to Morningstar's Dave Sekera.
Jeremy Glaser: For Morningstar.com, I'm Jeremy Glaser. I'm joined today by Senior Securities Analyst, Dave Sekera and Equity Analyst, Phil Gorham to look at Lorillard and how potential regulations from the FDA could impact bondholders.
Gentlemen, thanks for joining me today.
Jeremy Glaser does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.